Astral Laboratories Promoter ACESO Research Labs Acquires Additional 21,007 Shares
Astral Laboratories Limited disclosed that its promoter ACESO Research Labs LLP acquired 21,007 equity shares through open market transactions on BSE from March 11-19, 2026. The acquisition increased the promoter's shareholding from 4.64% to 4.69% of total share capital and from 4.45% to 4.50% of diluted capital. The disclosure was made under SEBI SAST Regulation 29(2) through Company Secretary Mahendra Kumar.
*this image is generated using AI for illustrative purposes only.
Astral Laboratories Limited has disclosed a share acquisition by its promoter entity ACESO Research Labs LLP under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The transaction represents a strategic increase in the promoter's stake in the pharmaceutical company.
Transaction Details
ACESO Research Labs LLP executed the share purchase through open market transactions on the BSE platform. The acquisition involved 21,007 equity shares, increasing the promoter's shareholding in the company.
| Parameter | Details |
|---|---|
| Shares Acquired | 21,007 |
| Transaction Period | March 11-19, 2026 |
| Exchange | BSE Limited |
| Transaction Type | Open market purchase |
| Regulation | SEBI SAST Regulation 29(2) |
Shareholding Changes
The acquisition resulted in an increase in ACESO Research Labs LLP's shareholding in Astral Laboratories Limited. The promoter's stake grew from 4.64% to 4.69% following the transaction.
| Shareholding Position | Before Transaction | After Transaction |
|---|---|---|
| Number of Shares | 1,959,284 | 1,980,291 |
| Percentage Holding (Total Share Capital) | 4.64% | 4.69% |
| Percentage Holding (Diluted Capital) | 4.45% | 4.50% |
| Change in Shares | - | +21,007 |
Company Capital Structure
The disclosure reveals Astral Laboratories Limited's current capital structure, with the paid-up capital remaining unchanged post-transaction.
| Capital Type | Amount | Number of Shares |
|---|---|---|
| Paid-Up Capital | ₹42.22 crore | 42,215,632 shares of ₹10 each |
| Total Diluted Capital | ₹43.99 crore | 43,985,632 shares of ₹10 each |
Regulatory Compliance
Astral Laboratories Limited submitted the disclosure to BSE Limited on March 19, 2026, through its Company Secretary and Compliance Officer, Mahendra Kumar. The disclosure was made under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, specifically Regulation 29(2).
About the Entities
ACESO Research Labs LLP operates from Bangalore, Karnataka, and is represented by Designated Partner Ravikanti Shailaja (DIN: 07629653). Astral Laboratories Limited, formerly known as Macro International Limited, is incorporated under CIN L74120UP1993PLC015605 with its registered office in Noida, Uttar Pradesh, and corporate office in Hyderabad, Telangana. The company trades on BSE under scrip code 512600 with security ID ASTALLTD.
Historical Stock Returns for Astal Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.66% | -8.73% | -13.97% | -21.96% | -20.14% | +668.11% |
Will ACESO Research Labs LLP continue increasing its stake in Astral Laboratories to reach the 5% threshold that would trigger additional disclosure requirements?
How might this promoter stake increase signal potential strategic initiatives or expansion plans for Astral Laboratories in the pharmaceutical sector?
Could this acquisition pattern indicate preparation for a larger corporate restructuring or merger within the promoter group's portfolio companies?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
